8-K: Recursion Pharmaceuticals Completes Acquisition of Exscientia, Forming AI-Powered Drug Discovery Giant

Recursion Pharmaceuticals has finalized its acquisition of Exscientia, creating a combined entity poised to lead in AI-driven drug discovery and development.

Summary

• Recursion Pharmaceuticals has completed its acquisition of Exscientia, making Exscientia a wholly-owned subsidiary.
• The transaction involved Recursion acquiring all of Exscientia's issued share capital in exchange for 0.7729 shares of Recursion Class A Common Stock for each Exscientia ordinary share.
• A total of 102,138,419 shares of Recursion Class A Common Stock were issued to Exscientia shareholders.
• Exscientia's ADSs have ceased trading on Nasdaq and will be delisted.
• Outstanding Exscientia share options and restricted stock units were converted into Recursion options and RSUs, with adjustments to reflect the exchange ratio.
• The combined company has a pipeline of more than 10 clinical and preclinical programs, along with 10 advanced discovery programs.
• The combined entity has received approximately $450 million in upfront and milestone payments from partnerships, with the potential for over $20 billion in additional milestone payments.
• The company's platform combines Recursion's OS with Exscientia's chemical design and synthesis methods, leveraging over 60 petabytes of proprietary data.
• The combined company will have approximately 800 employees, with headquarters in Salt Lake City and other primary offices in various locations.

Sentiment

Score: 8

Explanation: The document is very positive, highlighting the successful completion of a major acquisition and the potential for future growth and innovation. The tone is optimistic and forward-looking, with a focus on the combined company's strengths and opportunities.

Positives

• The acquisition creates a vertically-integrated and technology-enabled drug discovery platform.
• The combined company has a robust pipeline of clinical and preclinical programs.
• The company has significant potential for future milestone payments from partnerships.
• The combined platform leverages a large amount of proprietary data.
• The company has a strong leadership team with experience in both technology and life sciences.

Negatives

• Exscientia's ADSs have been delisted from Nasdaq.
• There are costs associated with integrating the two companies.
• The company is undergoing executive leadership changes.

Risks

• The company faces risks related to integrating Exscientia's business with Recursion's.
• There are risks associated with conducting business internationally.
• The company is subject to market and economic conditions, including competition and regulatory approvals.
• There are risks related to the market value of Recursion's common stock.
• The company may face challenges in retaining key personnel.

Future Outlook

The combined company aims to accelerate drug discovery, reduce costs, and create virtual cells for clinical trials at scale. They anticipate multiple clinical program milestones over the next 18 months and expect to leverage their combined data and AI capabilities to drive innovation and value creation.

Management Comments

• Chris Gibson, Ph.D., Co-Founder and CEO of Recursion, stated that the combination positions them as the leader in AI-enabled drug discovery and development.
• David Hallett, Ph.D., former CSO and Interim CEO of Exscientia and newly appointed Chief Scientific Officer at Recursion, said that the combined strength of real-world data and models will redefine the space by shrinking timelines and costs.

Industry Context

This merger reflects a growing trend of consolidation in the AI-driven drug discovery space, as companies seek to combine resources and expertise to accelerate the development of new therapies. The combination of Recursion's large-scale data generation and Exscientia's AI-powered drug design capabilities positions the new entity as a significant player in the industry.

Comparison to Industry Standards

• The combined company's pipeline of over 10 clinical and preclinical programs is comparable to other leading biotech companies in the AI-driven drug discovery space, such as Schrodinger and Relay Therapeutics.
• The potential for over $20 billion in milestone payments is significant and indicates strong commercial interest in their programs, similar to other companies with extensive partnership networks like BioNTech.
• The use of a unified operating system (OS) with both first-in-class and best-in-class capabilities is a strategic approach to drug discovery, similar to how companies like Insitro are leveraging their platforms.
• The focus on rare diseases and oncology aligns with industry trends, as these areas often have high unmet needs and significant market potential, similar to companies like Vertex Pharmaceuticals and Alnylam Pharmaceuticals.
• The company's emphasis on data-driven drug discovery and the use of AI to accelerate the process is consistent with the broader industry shift towards technology-enabled drug development, as seen in companies like AbCellera and Atomwise.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders will see a change in the company's structure and potential for increased value through the combined entity.
• Employees will experience changes in leadership and potential integration of teams.
• Customers and partners will benefit from the combined company's enhanced capabilities and expanded pipeline.
• Suppliers may see changes in procurement and supply chain management.
• Creditors will be impacted by the financial changes resulting from the acquisition.

Next Steps

• The company will present initial Phase 1 monotherapy safety and PK/PD data for REC-617 at the AACR Special Conference on December 9, 2024.
• A webinar will follow the REC-617 data presentation on December 10, 2024.
• The company expects a development candidate nomination for REV102 in Q4 2024.
• Phase 1b/2 safety and early efficacy data for REC-4881 is expected in H1 2025.
• PFS6 futility analysis for REC-2282 is expected by H1 2025.
• Phase 1 first patient dosed (FPD) for REC-3565 is expected in Q1 2025.
• Phase 1 first patient dosed (FPD) for REC-4539 is expected in H1 2025.
• Further data for REC-994 will be shared at an upcoming medical conference/publication/webinar in H1 2025, with a regulatory update expected by H2 2025.
• Phase 2 update for REC-394 is expected in Q1 2026.
• Phase 1 dose-escalation data update for REC-1245 is expected in H1 2026.
• IND-enabling studies for REC-4209 are ongoing.

Key Dates

Keywords

AI drug discovery, drug development, acquisition, biotechnology, pharmaceuticals, machine learning, clinical trials, partnerships, pipeline, genomics